Mortality Up With No Revascularization in STEMI

This article originally appeared here.
Share this content:
Mortality Up With No Revascularization in STEMI
Mortality Up With No Revascularization in STEMI

FRIDAY, June 24, 2016 (HealthDay News) -- Mortality is increased for patients with non-ST-segment elevation myocardial infarction (NSTEMI) who do not undergo coronary revascularization, according to a study published in the July 1 issue of The American Journal of Cardiology.

Alex Blatt, M.D., from the Assaf Harofeh Medical Center in Zerifin, Israel, and colleagues examined the clinical characteristics, management strategies, and outcomes of 3,198 patients with NSTEMI. Patients were categorized into three groups: no catheterization (no angio), catheterization with revascularization (angio-revascularized), and catheterization without revascularization (angio-nonrevascularized). Seventy-nine percent of participants underwent coronary angiography performed during the index hospitalization, 59 percent of whom underwent revascularization.

The researchers found that the rate of administration of evidence-based therapies at index hospitalization was significantly higher for the angio-revascularized group compared with the other groups. Patients in the no-angio group experienced significantly higher risk for one-year mortality compared with those in the angio-revascularized and angio-nonrevascularized groups (hazard ratios, 2.04 and 1.21, respectively). In each risk subset analyzed, including older age and increased creatinine levels, there was consistent risk associated with no revascularization.

"In conclusion, our data, from a large real-world contemporary experience, suggest that patients with NSTEMI who do not undergo coronary revascularization during the index hospitalization represent a greater risk and undertreated group with increased risk for long-term mortality," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »